When you purchase through tie-in on our site , we may earn an affiliate commission . Here ’s how it go .
free weight - loss drugs like Ozempic may decrease your risk of exposure of get 42 health conditions , but increase your chance of experiencing 19 others , fit in to one of the most comprehensive studies - of - its - kind to appointment .
Glucagon - like peptide 1 receptor agonist ( GLP-1RAs ) have become increasingly popularover the past decadefor the treatment oftype 2 diabetesandobesity , with versions likeOzempicandWegovybecoming household names .
Ozempic-style drugs may have an array of beneficial effects on the body, but not without risks, hints a large new study.
These drugs serve address diabetes bypromoting the release of insulin and help to reduce blood sugar grade . But they have also been linked to free weight loss , potentially by slowing down the digestion of food and curbing appetence . In 2024 , Wegovy also received regulative approval in the U.S. to treat heart disease , although the precise mechanics - of - action mechanism is ill-defined .
Evidence is additionally emerging to suggest that GLP-1RAs may help prevent the onslaught of conditions such asAlzheimer ’s diseaseand help patients to superintend others likesubstance - use disorders . However , concerns have also been raised regarding the negative side effects of contain GLP-1RAs , including reports ofgastrointestinal issues .
Related : Ozempic - like meds linked to high risk of pancreatitis , ' tum palsy ' than other weightiness - personnel casualty drugs
The findings may help healthcare providers to weigh up the risks and benefits of prescribing ozempic-style drugs to their patients, the study authors suggest.
Now , in a newfangled study , scientists have pile up what they say is the clear ever picture of the effectiveness and risks tie in with taking GLP-1RAs .
In the study , researchers assess the impact of have GLP-1RAs on the wellness of 215,000 people with eccentric 2 diabetes over around four days . They then compare these effects to a ascendence group of more than one million individuals who have unlike type of anti - diabetic drugs . Data on all participant was obtained from theU.S. Department of Veteran Affairs .
Overall , the researchers found that GLP-1RAs have many beneficial effects , some of which were previously recognize . For case , those who took GLP-1RAs had a 9 % , 8 % and 12 % reduced risk of having a affectionateness attack , deep vein thrombosis and Alzheimer ’s , respectively , equate to control . They were also less likely to arise inwardness - use disorders , including alcohol - use disorders and marijuana - use disorders ( both an 11 % low risk ) , as well as have a 12 % lower risk of experiencing bacterial infections .
These effects may somehow be linked to both the health benefits of physically losing weight , as well as other effects of GLP-1RAs in the body , such as reducinginflammationand influencing wages signaling in the psyche , Dr. Ziyad Al - Aly , field of study Centennial State - author and an assistant prof of medicine at Washington University , said during a Jan. 16 news conference .
However , these benefits did not come without risks , the researcher observed . For example , GLP-1RAs also increased masses ’s betting odds of develop gastrointestinal issues such as abdominal pain in the ass ( 12 % ) , plus low blood pressure ( 6 % higher risk ) and arthritis ( 11 % higher risk ) .
" We tend to think of drugs as being surgically designed to do only one thing , but the realness is , it ’s almost never like this , " Al - Aly said .
The sketch , which was published Monday ( Jan. 20 ) in the journalNature Medicine , primarily used data from old , lily-white males , meaning that the finding may not apply to other demographics .
Nevertheless , the hope is that healthcare providers could use the determination to resolve whether patients should take these drugs , reckon on their medical history , Al - Aly said .
" This [ study ] is a dandy good example of the note value of large databases of medical records data enabling not only a subject to measure safety profile but also likely new uses for an increasingly widely used therapy for diabetes and obesity,“Dr . Penny Ward , a visiting professor in pharmaceutic medicine at King ’s College London who was not involved in the research , say Live Science in an email .
The study was data-based , therefore it can not prove that GLP-1RAs stimulate these effect . To do this , a randomized controlled trial is needed , whereby the effects of GLP-1RAs are test against a control group in a tightly - regulate way .
— Watch out for Ozempic imitator contain unauthorized active ingredients , FDA warn
— How does the mental capacity regulate body system of weights ?
— Workout in a lozenge : Scientists move one step nearer to an exercise - mimic drug
Fortunately , such trial are currently afoot with results potentially usable in the next one to four years , saidDr . Naveed Sattar , a professor of cardiometabolic medicine at the University of Glasgow in Scotland , who was not involve in the research .
" Such test will lead us much closer to the Sojourner Truth , " hetold the U.K. Science Media Centre .
This article is for informational purpose only and is not mean to offer aesculapian advice .
